| Factor Information | |
|---|---|
| Data ID | 2696 |
| Factor | WHO functional class |
| Description | The WHO functional class improved significantly in both the VSD group and the PDA group. |
| Biomarker | NA |
| Classification | A6 (clinical factor - other) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | The potential effect of sildenafil on pulmonary arterial hypertension related to CHD may be associated with shunt location. |
| p Value | 0.002 |
| Conclusion | The WHO functional class improved significantly in both the VSD group and the PDA group. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 484 |
| CHD Type | isolated CHD |
| CHD Subtype | ASD/VSD/PDA |
| Reference | |
|---|---|
| PMID | 21678455 |
| Year | 2011 |
| Title | The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease |
| Sample | ||
|---|---|---|
| Population | adults | |
| Source | 12-week, prospective, open label, multicenter trial | |
| Region | Beijing, China | |
| Method | 12-week, prospective, open label, multicenter trial | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | VSD (12 Weeks)(Treatment) | VSD (Baseline)(Control) |
| Number | 24 | 24 |
| Age | 26.58 ± 9.61 years | 26.58 ± 9.61 years |
| Gender (Male: Female) | 08:16:00.000 | 08:16:00.000 |
| Marker Level | 1.8 ± 0.6 | 2.3 ± 0.4 |
